Brief: Akoustis Technologies Q1 Basic EPS USD -0.28
13/11/2023 12:30
Nov 13 (Reuters) - Akoustis Technologies Q1 net income USD -20.129 million. * Q1 operating expenses USD 20.57 million * Q1 gross profit USD -1.084 million * Q1 pretax profit USD -20.128 million * Q1 revenue USD 7.002 million vs. IBES estimate USD 7.08 million * Q1 operating income USD -21.654 million
Recent news on Aktis Oncology
See all newsAktis Oncology Q2 net loss widens on higher R&D, administrative costs
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
Aktis Oncology Q1 net loss widens on increased IPO-related expenses
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer (updated)
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut